S&P 500, Nasdaq Slip as Oil Jumps on Iran Tensions 
China Inflation Cools in July as CPI Misses Forecast, PPI Deflation Eases 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
Iran-Oman Near Strait of Hormuz Deal as Shipping Tensions Persist 
U.S. Unseals Charges Against Five Alleged CJNG Leaders, Raises Reward for New Cartel Chief 
Juan Orlando Hernandez Seeks Dismissal of Honduras Charges After Trump Pardon 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
SEC Moves to Dismiss Insider Trading Case Against Trump-Pardoned Terren Peizer 
Asian Stocks Mixed as RBA Holds Rates, Oil Risks Rise 
Wall Street Slips as Oil Prices Surge 5% on Iran-Hormuz Uncertainty 
Peru Court Frees Former President Ollanta Humala After Conviction Overturned 
Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
Civil Rights Groups Sue Trump Administration Over Childcare Funding Freeze and Influencer's Role 
Asian Currencies Steady as Markets Await U.S. Inflation Data 
Paramount-Warner Bros. Merger Delayed Until 2027 Amid Antitrust Lawsuit 
FCC Moves to Ban Imports of Foreign Military-Grade Drones Over Security Risks 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
